Using Biomarkers to Predict Memantine Effects in Alzheimer's Disease: A Proposal and Proof-Of-Concept Demonstration.

Aged Alzheimer Disease / drug therapy Biomarkers Cognition / drug effects Double-Blind Method Excitatory Amino Acid Antagonists / administration & dosage Female Humans Male Memantine / administration & dosage Neuropsychological Tests
Alzheimer’s disease event-related potentials memantine neurocognition prepulse inhibition

Journal

Journal of Alzheimer's disease : JAD
ISSN: 1875-8908
Titre abrégé: J Alzheimers Dis
Pays: Netherlands
ID NLM: 9814863

Informations de publication

Date de publication:
2021
Historique:
pubmed: 26 10 2021
medline: 21 1 2022
entrez: 25 10 2021
Statut: ppublish

Résumé

Memantine's benefits in Alzheimer's disease (AD) are modest and heterogeneous. We tested the feasibility of using sensitivity to acute memantine challenge to predict an individual's clinical response. Eight participants completed a double-blind challenge study of memantine (placebo versus 20 mg) effects on autonomic, subjective, cognitive, and neurophysiological measures, followed by a 24-week unblinded active-dose therapeutic trial (10 mg bid). Study participation was well tolerated. Subgroups based on memantine sensitivity on specific laboratory measures differed in their clinical response to memantine, some by large effect sizes. It appears feasible to use biomarkers to predict clinical sensitivity to memantine.

Identifiants

DOI: 10.3233/JAD-215029 PMID: 34690144 PMC: PMC8881988
pubmed: 34690144
pii: JAD215029
doi: 10.3233/JAD-215029
pmc: PMC8881988
mid: NIHMS1774668
doi:

Substances chimiques

Biomarkers 0
Excitatory Amino Acid Antagonists 0
Memantine W8O17SJF3T

Types de publication

Letter Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

1431-1438

Subventions

Organisme : NIA NIH HHS
ID : P30 AG062429
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG059640
Pays : United States
Organisme : NIMH NIH HHS
ID : R01 MH094320
Pays : United States

Références

CNS Neurol Disord Drug Targets. 2016;15(7):823-36
pubmed: 27189465
Brain Res Bull. 2007 May 30;72(4-6):275-83
pubmed: 17452287
J Alzheimers Dis. 2011;25(3):463-75
pubmed: 21471647
Lancet. 1990 Jul 7;336(8706):32-4
pubmed: 1973218
Neuropsychopharmacology. 2017 Dec;42(13):2633-2639
pubmed: 28425497
Neuropsychopharmacology. 2016 Jan;41(2):419-30
pubmed: 26062785
Ann Clin Transl Neurol. 2014 Mar 1;1(3):190-198
pubmed: 24839611
Am J Geriatr Psychiatry. 2006 Aug;14(8):704-15
pubmed: 16861375
Biol Psychol. 2003 Mar;62(3):175-95
pubmed: 12633977
J Alzheimers Dis. 2017;60(2):401-425
pubmed: 28922160
Neurobiol Aging. 2011 Jan;32(1):24-30
pubmed: 19237225
J Alzheimers Dis. 2008 Feb;13(1):97-107
pubmed: 18334761
J Alzheimers Dis. 2012;28(1):109-18
pubmed: 21955815
F1000Res. 2017 May 3;6:
pubmed: 28529691
Arch Clin Neuropsychol. 2008 Sep;23(5):603-12
pubmed: 18639437
Neuroscience. 2010 Jun 2;167(4):1175-82
pubmed: 20298759
Alzheimers Dement. 2007 Jan;3(1):7-17
pubmed: 19595910
Neurosci Biobehav Rev. 2019 Feb;97:70-84
pubmed: 30195932
Int J Psychophysiol. 2015 Feb;95(2):145-55
pubmed: 24681247
Am J Hum Genet. 2016 Oct 6;99(4):802-816
pubmed: 27616483
Neuropsychiatr Dis Treat. 2017 Jul 20;13:1909-1928
pubmed: 28790827
Neurobiol Aging. 2004 Sep;25(8):1045-50
pubmed: 15212829
Neuropsychopharmacology. 2020 Dec;45(13):2180-2188
pubmed: 32961542
Horm Res. 2007;68 Suppl 5:59-65
pubmed: 18174710
J Affect Disord. 1981 Dec;3(4):389-96
pubmed: 6459354
Neuroreport. 2001 Jun 13;12(8):1649-52
pubmed: 11409733
Psychiatry Clin Neurosci. 2006 Feb;60(1):55-62
pubmed: 16472359
J Neurol Neurosurg Psychiatry. 2005 Jan;76(1):106-8
pubmed: 15608006
Neurol Ther. 2017 Jun;6(1):131-144
pubmed: 28508250
Alzheimer Dis Assoc Disord. 2007 Jan-Mar;21(1):60-4
pubmed: 17334274
Nat Genet. 2013 Sep;45(9):1061-6
pubmed: 23933820
Ann N Y Acad Sci. 2015 May;1344:105-19
pubmed: 25752648
Front Aging Neurosci. 2013 Nov 20;5:79
pubmed: 24312051
Neurobiol Dis. 2016 Dec;96:75-83
pubmed: 27546057
Psychopharmacology (Berl). 2016 Jun;233(12):2399-410
pubmed: 27076209
JAMA Psychiatry. 2017 Jan 1;74(1):37-46
pubmed: 27926742
J Asthma. 2009 Sep;46(7):722-5
pubmed: 19728213
Expert Opin Drug Saf. 2009 Jan;8(1):89-109
pubmed: 19236221
Neuropsychopharmacology. 2009 Jun;34(7):1854-64
pubmed: 19242406
Alzheimers Dement. 2009 Sep;5(5):369-74
pubmed: 19751915
Biol Psychiatry Cogn Neurosci Neuroimaging. 2020 Jun;5(6):562-568
pubmed: 32340927
Cochrane Database Syst Rev. 2005 Jul 20;(3):CD003154
pubmed: 16034889
Clin Neurophysiol. 2006 Sep;117(9):1990-5
pubmed: 16887381
Neurobiol Aging. 2015 Sep;36(9):2544-54
pubmed: 26119223
Psychol Med. 2018 Jan;48(1):72-81
pubmed: 28528597
Clin EEG Neurosci. 2016 Jan;47(1):48-55
pubmed: 25253434

Auteurs

Neal R Swerdlow (NR)

Department of Psychiatry, School of Medicine, University of California, San Diego, La Jolla, CA, USA.

Juliana E Kotz (JE)

Department of Psychiatry, School of Medicine, University of California, San Diego, La Jolla, CA, USA.

Yash B Joshi (YB)

Department of Psychiatry, School of Medicine, University of California, San Diego, La Jolla, CA, USA.
VISN-22 Mental Illness, Research, Education and Clinical Center (MIRECC), VA San Diego Healthcare System, San Diego, CA, USA.

Jo Talledo (J)

Department of Psychiatry, School of Medicine, University of California, San Diego, La Jolla, CA, USA.

Joyce Sprock (J)

Department of Psychiatry, School of Medicine, University of California, San Diego, La Jolla, CA, USA.
VISN-22 Mental Illness, Research, Education and Clinical Center (MIRECC), VA San Diego Healthcare System, San Diego, CA, USA.

Juan L Molina (JL)

Department of Psychiatry, School of Medicine, University of California, San Diego, La Jolla, CA, USA.
VISN-22 Mental Illness, Research, Education and Clinical Center (MIRECC), VA San Diego Healthcare System, San Diego, CA, USA.

Branko Huisa (B)

Department of Neurosciences, School of Medicine, University of California, San Diego, La Jolla, CA, USA.

Steven F Huege (SF)

Department of Psychiatry, School of Medicine, University of California, San Diego, La Jolla, CA, USA.

Jairo Alberto Romero (JA)

Department of Medicine, School of Medicine, University of California, San Diego, La Jolla, CA, USA.

Michael J Walsh (MJ)

Department of Psychiatry, School of Medicine, University of California, San Diego, La Jolla, CA, USA.

Lisa Delano-Wood (L)

Department of Psychiatry, School of Medicine, University of California, San Diego, La Jolla, CA, USA.

Gregory A Light (GA)

Department of Psychiatry, School of Medicine, University of California, San Diego, La Jolla, CA, USA.
VISN-22 Mental Illness, Research, Education and Clinical Center (MIRECC), VA San Diego Healthcare System, San Diego, CA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Sujet âgé › Using Biomarkers to Predict Memantine Effects...
questionsmedicales.fr › Troubles mentaux › Troubles neurocognitifs › Démence › Maladie d'Alzheimer › Using Biomarkers to Predict Memantine Effects...
questionsmedicales.fr › Facteurs biologiques › Marqueurs biologiques › Using Biomarkers to Predict Memantine Effects...
questionsmedicales.fr › Phénomènes psychologiques › Processus mentaux › Cognition › Using Biomarkers to Predict Memantine Effects...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Méthodologie en recherche épidémiologique › Méthode en double aveugle › Using Biomarkers to Predict Memantine Effects...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Effets physiologiques des médicaments › Agents neuromédiateurs › Agents des acides aminés excitateurs › Antagonistes des acides aminés excitateurs › Using Biomarkers to Predict Memantine Effects...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Using Biomarkers to Predict Memantine Effects...
questionsmedicales.fr › Composés chimiques organiques › Hydrocarbures › Hydrocarbures cycliques › Amantadine › Mémantine › Using Biomarkers to Predict Memantine Effects...
questionsmedicales.fr › Disciplines et activités comportementales › Tests psychologiques › Tests neuropsychologiques › Using Biomarkers to Predict Memantine Effects...